ArticleExperimental and therapeutic medicine2026
Wogonin as a potential therapeutic agent for psoriasis: Core target identification and validation.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wogonin exhibits therapeutic effects in various skin diseases. However, the pharmacological effects and mechanisms of wogonin against psoriasis remain unclear. In the present study, the potential targets of wogonin were predicted and disease-related targets were obtained using Gene Expression Omnibus datasets. Intersection targets were identified using Venny 2.1.0 software, followed by input into the Search Tool for the Retrieval of Interacting Genes/Proteins database to generate a drug-target-disease visual network using Cytoscape 3.10.1. Core targets were obtained by protein-protein interaction analysis and the intersection targets were enriched through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. The binding of wogonin to its core targets was evaluated using molecular docking. Furthermore, a psoriasis mouse model was constructed to assess the therapeutic effect of wogonin on skin lesions, and core targets of wogonin were verified by immunohistochemistry, including cyclin-D1 (CCND1), matrix metalloproteinase-9 (MMP9), cyclin-B1, cyclin-A2 (CCNA2), cyclin-dependent kinase 1 and androgen receptor. Molecular docking analysis revealed interactions between wogonin and these targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.